Literature DB >> 24574394

In vivo ablation of type I interferon receptor from cardiomyocytes delays coxsackieviral clearance and accelerates myocardial disease.

Nadine Althof1, Stephanie Harkins, Christopher C Kemball, Claudia T Flynn, Mehrdad Alirezaei, J Lindsay Whitton.   

Abstract

UNLABELLED: Acute coxsackievirus B3 (CVB3) infection is one of the most prevalent causes of acute myocarditis, a disease that frequently is identified only after the sudden death of apparently healthy individuals. CVB3 infects cardiomyocytes, but the infection is highly focal, even in the absence of a strong adaptive immune response, suggesting that virus spread within the heart may be tightly constrained by the innate immune system. Type I interferons (T1IFNs) are an obvious candidate, and T1IFN receptor (T1IFNR) knockout mice are highly susceptible to CVB3 infection, succumbing within a few days of challenge. Here, we investigated the role of T1IFNs in the heart using a mouse model in which the T1IFNR gene can be ablated in vivo, specifically in cardiomyocytes. We found that T1IFN signaling into cardiomyocytes contributed substantially to the suppression of viral replication and infectious virus yield in the heart; in the absence of such signaling, virus titers were markedly elevated by day 3 postinfection (p.i.) and remained high at day 12 p.i., a time point at which virus was absent from genetically intact littermates, suggesting that the T1IFN-unresponsive cardiomyocytes may act as a safe haven for the virus. Nevertheless, in these mice the myocardial infection remained highly focal, despite the cardiomyocytes' inability to respond to T1IFN, indicating that other factors, as yet unidentified, are sufficient to prevent the more widespread dissemination of the infection throughout the heart. The absence of T1IFN signaling into cardiomyocytes also was accompanied by a profound acceleration and exacerbation of myocarditis and by a significant increase in mortality. IMPORTANCE: Acute coxsackievirus B3 (CVB3) infection is one of the most common causes of acute myocarditis, a serious and sometimes fatal disease. To optimize treatment, it is vital that we identify the immune factors that limit virus spread in the heart and other organs. Type I interferons play a key role in controlling many virus infections, but it has been suggested that they may not directly impact CVB3 infection within the heart. Here, using a novel line of transgenic mice, we show that these cytokines signal directly into cardiomyocytes, limiting viral replication, myocarditis, and death.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24574394      PMCID: PMC3993796          DOI: 10.1128/JVI.00184-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  99 in total

1.  Incidence of myocarditis. A 10-year autopsy study from Malmö, Sweden.

Authors:  M B Gravanis; N H Sternby
Journal:  Arch Pathol Lab Med       Date:  1991-04       Impact factor: 5.534

2.  Twenty year autopsy statistics of myocarditis incidence in Japan.

Authors:  S Wakafuji; R Okada
Journal:  Jpn Circ J       Date:  1986-12

Review 3.  The pharmacology and clinical uses of tamoxifen.

Authors:  B J Furr; V C Jordan
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

4.  Severe arrhythmias in Coxsackievirus B3 myopericarditis.

Authors:  C Ward
Journal:  Arch Dis Child       Date:  1978-02       Impact factor: 3.791

Review 5.  Autoimmunity in coxsackievirus B3 induced myocarditis.

Authors:  Sally A Huber
Journal:  Autoimmunity       Date:  2006-02       Impact factor: 2.815

6.  Induction of chemokine and cytokine genes in astrocytes following infection with Theiler's murine encephalomyelitis virus is mediated by the Toll-like receptor 3.

Authors:  Eui Young So; Min Hyung Kang; Byung S Kim
Journal:  Glia       Date:  2006-06       Impact factor: 7.452

7.  Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration.

Authors:  Y Akwa; D E Hassett; M L Eloranta; K Sandberg; E Masliah; H Powell; J L Whitton; F E Bloom; I L Campbell
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

8.  A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis.

Authors:  J Aicardi; F Goutières
Journal:  Ann Neurol       Date:  1984-01       Impact factor: 10.422

9.  Trex1 prevents cell-intrinsic initiation of autoimmunity.

Authors:  Daniel B Stetson; Joan S Ko; Thierry Heidmann; Ruslan Medzhitov
Journal:  Cell       Date:  2008-08-22       Impact factor: 41.582

10.  Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway.

Authors:  Christopher C Kemball; Stephanie Harkins; Jason K Whitmire; Claudia T Flynn; Ralph Feuer; J Lindsay Whitton
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

View more
  21 in total

1.  MAVS-dependent host species range and pathogenicity of human hepatitis A virus.

Authors:  Asuka Hirai-Yuki; Lucinda Hensley; David R McGivern; Olga González-López; Anshuman Das; Hui Feng; Lu Sun; Justin E Wilson; Fengyu Hu; Zongdi Feng; William Lovell; Ichiro Misumi; Jenny P-Y Ting; Stephanie Montgomery; John Cullen; Jason K Whitmire; Stanley M Lemon
Journal:  Science       Date:  2016-09-15       Impact factor: 47.728

2.  Immunological and pathological consequences of coxsackievirus RNA persistence in the heart.

Authors:  Claudia T Flynn; Taishi Kimura; Kwesi Frimpong-Boateng; Stephanie Harkins; J Lindsay Whitton
Journal:  Virology       Date:  2017-12       Impact factor: 3.616

3.  Chromosomal mapping of the αMHC-MerCreMer transgene in mice reveals a large genomic deletion.

Authors:  Stephanie Harkins; J Lindsay Whitton
Journal:  Transgenic Res       Date:  2016-05-10       Impact factor: 2.788

4.  Spontaneous activation of a MAVS-dependent antiviral signaling pathway determines high basal interferon-β expression in cardiac myocytes.

Authors:  Efraín E Rivera-Serrano; Nicole DeAngelis; Barbara Sherry
Journal:  J Mol Cell Cardiol       Date:  2017-08-16       Impact factor: 5.000

5.  Functional Consequences of RNA 5'-Terminal Deletions on Coxsackievirus B3 RNA Replication and Ribonucleoprotein Complex Formation.

Authors:  Nicolas Lévêque; Magali Garcia; Alexis Bouin; Joseph H C Nguyen; Genevieve P Tran; Laurent Andreoletti; Bert L Semler
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

6.  Sex-Dependent Intestinal Replication of an Enteric Virus.

Authors:  Christopher M Robinson; Yao Wang; Julie K Pfeiffer
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

Review 7.  Intricacies of cardiac damage in coxsackievirus B3 infection: implications for therapy.

Authors:  Chandirasegaran Massilamany; Arunakumar Gangaplara; Jay Reddy
Journal:  Int J Cardiol       Date:  2014-10-18       Impact factor: 4.164

Review 8.  Coxsackievirus B3-Its Potential as an Oncolytic Virus.

Authors:  Anja Geisler; Ahmet Hazini; Lisanne Heimann; Jens Kurreck; Henry Fechner
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

9.  TRIM7 inhibits enterovirus replication and promotes emergence of a viral variant with increased pathogenicity.

Authors:  Wenchun Fan; Katrina B Mar; Levent Sari; Ilona K Gaszek; Qiang Cheng; Bret M Evers; John M Shelton; Mary Wight-Carter; Daniel J Siegwart; Milo M Lin; John W Schoggins
Journal:  Cell       Date:  2021-05-31       Impact factor: 66.850

Review 10.  Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.

Authors:  Huitao Liu; Honglin Luo
Journal:  Viruses       Date:  2021-06-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.